Business
Eli Lilly hikes price of diabetes drug Mounjaro in UK as Trump pressures pharma to align drug costs
Mounjaro manufactured by Eli Lilly and Company packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on April 9, 2024.
Nurphoto | Nurphoto | Getty Images
Eli Lilly on Thursday said it is raising the list price of its blockbuster diabetes drug Mounjaro in the U.K. starting in September, as President Donald Trump pressures drugmakers to lower U.S. drug prices and hike them abroad.
In a statement, Eli Lilly said it reached an agreement with the U.K. government to increase the list price of the weekly injection, while “maintaining access” for patients covered under the publicly funded health-care system, the National Health Service, or NHS.
Eli Lilly told CNBC that the price hike will not affect the drug’s availability under NHS, and it wants to work with the government to boost access. The company added that it does not determine prices that private health-care providers set, but is working with them to ensure access to Mounjaro.
In a statement on Thursday, NHS said Mounjaro’s list price increase “will not affect NHS commissioning of tirzepatide in England for eligible people living with obesity, based on clinical priority, or as a treatment for type 2 diabetes.” Tirzepatide is the active ingredient in Mounjaro and its counterpart for weight loss, Zepbound.
Mounjaro’s current list price in the UK ranges from £92 (about $124.89) to £122 a month, depending on the dose size, according to Eli Lilly. The drug’s new list price will increase to between £133 and £330 starting on Sept. 1.
The company added that it is working with certain governments and expects to make pricing adjustments in those countries by that date. In the U.S., the list price for a month’s supply of Mounjaro is $1,079.77 before insurance and other rebates.
Eli Lilly said it supports the Trump administration’s goal of keeping the U.S. the “world’s leading destination for biopharmaceutical research and manufacturing, and the objective of more fairly sharing the costs of breakthrough medical research across developed countries.”
“This rebalancing may be difficult, but it means the prices for medicines paid by governments and health systems need to increase in other developed markets like Europe in order to make them lower in the US,” the company said in the statement.
The announcement comes after Trump in July sent separate letters to 17 drugmakers, including Eli Lilly, calling on them to take steps to lower drug prices by Sept. 29. The move built on the president’s executive order in May reviving a controversial plan – the “most favored nation” policy – that aims to slash drug costs by tying the prices of some medicines in the U.S. to the significantly lower ones abroad.
U.S. prescription drug prices are two-to-three times higher on average than those in other developed nations – and up to 10 times more than in certain countries, according to the Rand Corp., a public policy think tank. Trump has said he wants to narrow that gap to stop Americans from being “ripped off.”
Eli Lilly’s announcement on Thursday comes as the industry braces for Trump’s planned tariffs on pharmaceuticals imported into the U.S. In its statement, the company said it opposes those tariffs, arguing they will “raise costs, limit patient access, and undermine American leadership, especially for companies already investing heavily in domestic manufacturing.”
In recent months, Eli Lilly was among several drugmakers to announce new plans to invest in U.S. manufacturing sites.
The government on Thursday kept petrol and high-speed diesel (HSD) prices unchanged at Rs253.17 per litre and Rs257.08 per litre respectively, for the coming fortnight, starting from January 16.
This decision was notified in a press release issued by the Petroleum Division.
Earlier, it was expected that the prices of all petroleum products would go down by up to Rs4.50 per litre (over 1pc each) today in view of variation in the international market.
Petrol is primarily used in private transport, small vehicles, rickshaws, and two-wheelers, and directly impacts the budgets of the middle and lower-middle classes.
Meanwhile, most of the transport sector runs on HSD. Its price is considered inflationary, as it is mostly used in heavy transport vehicles, trains, and agricultural engines such as trucks, buses, tractors, tube wells, and threshers, and particularly adds to the prices of vegetables and other eatables.
The government is currently charging about Rs100 per litre on petrol and about Rs97 per litre on diesel.
One of Britain’s most prolific rail fare dodgers could face jail after admitting dozens of travel offences.
Charles Brohiri, 29, pleaded guilty to travelling without buying a ticket a total of 112 times over a two-year period, Westminster Magistrates’ Court heard.
He could be ordered to pay more than £18,000 in unpaid fares and legal costs, the court was told.
He will be sentenced next month.
District Judge Nina Tempia warned Brohiri “could face a custodial sentence because of the number of offences he has committed”.
He pleaded guilty to 76 offences on Thursday.
It came after he was convicted in his absence of 36 charges at a previous hearing.
During Thursday’s hearing, Judge Tempia dismissed a bid by Brohiri’s lawyers to have the 36 convictions overturned.
They had argued the prosecutions were unlawful because they had not been brought by a qualified legal professional.
But Judge Tempia rejected the argument, saying there had been “no abuse of this court’s process”.
JSW Jetour T2 Launch: JSW Motors Limited, the passenger vehicle arm of the JSW Group, is reportedly preparing to enter the Indian car market this year. It has partnered with Jetour, a China-based automotive brand owned by Chery Automobile, and the Jetour T2 SUV could be the company’s first product, according to the reports.
Media reports suggest that the launch will happen independently and not under the JSW MG Motor India joint venture. The SUV will wear a JSW badge and name, instead of the Jetour branding. The upcoming SUV will be assembled at JSW’s upcoming greenfield manufacturing facility in Chhatrapati Sambhaji Nagar, Maharashtra.
According to the reports, the company plans to have the vehicle on sale by the third quarter of this year. With this move, JSW aims to establish itself as a standalone carmaker in India.
Expected Powertrain
The SUV is likely to arrive with a 1.5-litre plug-in hybrid setup. Internationally, this hybrid powertrain is offered with both front-wheel drive and all-wheel drive options. It is still unclear which version will be introduced in India.
Design
In terms of design, the T2 is a large and rugged-looking SUV. It has a boxy and upright stance, similar to vehicles like the Land Rover Defender. Despite its tough appearance, it uses a monocoque chassis instead of a ladder-frame construction.
Size
The SUV measures around 4.7 metres in length and nearly 2 metres in width. This makes it larger than the Tata Safari, even though it is a five-seater. A longer 7-seat version is also sold in some markets.
Price
Pricing details for India are yet to be announced. For reference, the front-wheel-drive five-seat T2 i-DM is priced at AED 1,44,000 (around Rs 35 lakh) in the UAE.
Jetour
Jetour is a brand owned by Chinese automaker Chery. Launched in 2018, it focuses mainly on SUVs and is present in markets across China, the Middle East, Africa, Southeast Asia and Latin America.
Xreal files patent suit against rival smart glasses maker Viture
Princess Kate crowned England’s Great with fiery Lioness spirit
Soshiotsuki wows with international debut at Pitti Uomo 109
-
Politics1 week agoUK says provided assistance in US-led tanker seizure
-
Entertainment1 week agoDoes new US food pyramid put too much steak on your plate?
-
Entertainment1 week agoWhy did Nick Reiner’s lawyer Alan Jackson withdraw from case?
-
Business1 week agoTrump moves to ban home purchases by institutional investors
-
Sports5 days agoClock is ticking for Frank at Spurs, with dwindling evidence he deserves extra time
-
Sports1 week agoPGA of America CEO steps down after one year to take care of mother and mother-in-law
-
Business1 week agoBulls dominate as KSE-100 breaks past 186,000 mark – SUCH TV
-
Sports6 days ago
Commanders go young, promote David Blough to be offensive coordinator